Diffuse Large B-Cell Lymphoma
Conditions
Keywords
DLBCL, MEDI4736, durvalumab, tremelimumab, AZD9150, anti-PD-L1, anti-CTLA-4, immunotherapy, IMTC, STAT3
Brief summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Detailed description
This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
Interventions
DRUGMEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
DRUGtremelimumab
Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
DRUGAZD9150
AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
Sponsors
MedImmune LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy 3. Eastern Cooperative Group (ECOG) performance status of 0 or 1 4. Measurable disease by International Working Group (IWG) response criteria for lymphoma 5. Adequate organ and marrow function
Exclusion criteria
1. Previous immune-mediated therapy 2. Subjects with prior ASCT or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded. 3. Documented current central nervous system involvement 3\. Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events | Screening through 90 days after the last dose of study medication | — |
| Number of subjects experiencing dose-limiting toxicities | First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150 | Changes from baseline in laboratory parameters, vital signs, and ECGs |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response | Screening though 3 years after the last subject receives the first dose of study medication |
| Progression Free survival | Screening though 3 years after the last subject receives the first dose of study medication |
| Time to progression | Screening though 3 years after the last subject receives the first dose of study medication |
| Event free survival | Screening though 3 years after the last subject receives the first dose of study medication |
| Overall survival | Screening though 3 years after the last subject receives the first dose of study medication |
| MEDI4736 Maximum Plasma Concentration (Cmax) | Measured at defined study visits from time of first dose through end of treatment |
| Tremelimumab Maximum Plasma Concentration (Cmax) | Measured at defined study visits from time of first dose through end of treatment |
| AZD9150 Maximum Plasma Concentration (Cmax) | Measured at defined study visits from time of first dose through end of treatment |
| Number of subjects who develop anti-drug antibodies (ADA) | Screening through 90 days after last dose of study medication |
| Tremelimumab Minimum Plasma Concentration (Cmin) | Measured at defined study visits from time of first dose through end of treatment |
| AZD9150 Minimum Plasma Concentration (Cmin) | Measured at defined study visits from time of first dose through end of treatment |
| Individual MEDI4736 Concentrations | Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) |
| Individual tremelimumab Concentrations | Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) |
| Individual AZD9150 Concentrations | Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) |
| Change from baseline of STAT3 RNA (signal transducer and activator of transcription) | Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months) |
| Baseline PD-L1 protein expression within the tumor | Measured on tumor samples provided at screening |
| MEDI4736 Minimum Plasma Concentration (Cmin) | Measured at defined study visits from time of first dose through end of treatment |
| Time to Response | Screening though 3 years after the last subject receives the first dose of study medication |
Countries
France, Ireland, United Kingdom, United States
Outcome results
None listed